Listen to this story
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowThis audio file is brought to you by 
0:00
0:00
Loading audio file, please wait.
Eli Lilly and Co.’s depression drug Cymbalta dampened pain in patients with fibromyalgia and has asked the Food and Drug Administration to approve it for secondary use, the Indianapolis pharmaceutical maker said today. Patients experienced less pain beginning a week after taking the treatment, a study showed.
Two percent to 4 percent of Americans, mostly women, suffer from the chronic condition, which causes fatigue as well as pain in muscles, ligaments and tendons.
Cymbalta generated $519.5 million of Lilly’s $4.6 billion in second-quarter sales.
Please enable JavaScript to view this content.